5 completed, 2 recruiting, 1 not yet recruiting. 6 Phase 1, 3 Phase 2.
By phase and status
Follow HER2 Mutation: new trials by email Literature Review of HER2 Mutation trials Research Report on HER2 Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations. Zongertinib (BI 1810631), Fulvestrant - Advanced Breast Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer Phase 2 Not yet recruiting 25 2026-10-04 2026-06-01 A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) BAY2927088 - Advanced Solid Tumors, HER2 Mutation Phase 2 Recruiting 111 2025-02-13 2026-11-04 A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants BAY2927088, Midazolam - Advanced Non-small Cell Lung Cancer, EGFR Mutation Phase 1 Completed 15 2024-04-17 2024-07-03 A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants BAY2927088, Itraconazole, Carbamazepine - Advanced Non-small Cell Lung Cancer, EGFR Mutation Phase 1 Completed 30 2024-04-10 2024-06-20 A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants BAY2927088, Esomeprazole, Food - Advanced Non-small Cell Lung Cancer, EGFR Mutation Phase 1 Completed 21 2024-03-29 2024-07-05 A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants BAY2927088, Dabigatran etexilate, Rosuvastatin - Advanced Non-small Cell Lung Cancer, EGFR Mutation Phase 1 Completed 15 2024-03-25 2024-07-05 A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants BAY2927088 coated tablet 10 mg, [14C]-BAY2927088 solution for infusion, [14C]-BAY2927088 oral solution - Advanced Non-small Cell Lung Cancer, EGFR Mutation Phase 1 Completed 8 2024-01-25 2024-06-28 First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) BAY2927088_formulation A, BAY2927088_formulation B_1, BAY2927088_formulation B_2 - Advanced Non-small Cell Lung Cancer, EGFR Mutation Phase 1 / Phase 2 Recruiting 430 2021-10-25 2026-10-21
Narrower conditions Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Gallbladder Neoplasms (1) · Gastrointestinal Neoplasms (1) · Gastrointestinal Stromal Tumors (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Sarcoma (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1) · Uterine Cervical Neoplasms (1)
Broader conditions Neoplasms (2) · Neoplasms by Site (2) · Adnexal Diseases (1) · Biliary Tract Diseases (1) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Esophageal Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
Interventions Carbamazepine (1) · Dabigatran (1) · Esomeprazole (1) · Food (1) · Fulvestrant (1) · Itraconazole (1) · Midazolam (1) · Rosuvastatin Calcium (1)
Sponsors Bayer (7) · MedSIR (1)
Countries United States (5) · China (2) · France (2) · Italy (2) · Japan (2) · Netherlands (2) · South Korea (2) · Spain (2) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Denmark (1) · Hong Kong (1) · Israel (1)
Results publications PMID 41104928
NIH funding 2023 (1)